Papillary Thyroid Cancer - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 106 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Papillary Thyroid Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Papillary Thyroid Cancer - Pipeline Review, H1 2016', provides an overview of the Papillary Thyroid Cancer pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Papillary Thyroid Cancer and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Papillary Thyroid Cancer
- The report reviews pipeline therapeutics for Papillary Thyroid Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Papillary Thyroid Cancer therapeutics and enlists all their major and minor projects
- The report assesses Papillary Thyroid Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Papillary Thyroid Cancer

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Papillary Thyroid Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Papillary Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Papillary Thyroid Cancer Overview 7
Therapeutics Development 8
Pipeline Products for Papillary Thyroid Cancer - Overview 8
Pipeline Products for Papillary Thyroid Cancer - Comparative Analysis 9
Papillary Thyroid Cancer - Therapeutics under Development by Companies 10
Papillary Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11
Papillary Thyroid Cancer - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Papillary Thyroid Cancer - Products under Development by Companies 15
Papillary Thyroid Cancer - Products under Investigation by Universities/Institutes 16
Papillary Thyroid Cancer - Companies Involved in Therapeutics Development 17
Exelixis, Inc. 17
Genzyme Corporation 18
Ignyta, Inc. 19
Novartis AG 20
Pfizer Inc. 21
Plexxikon Inc. 22
Vaccinex, Inc. 23
Papillary Thyroid Cancer - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
cabozantinib s-malate - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
CLM-3 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
dabrafenib mesylate - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
entrectinib - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
everolimus - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
pasireotide - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PLX-7486 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
PLX-8394 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
sunitinib malate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
vandetanib - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
VX-15 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Papillary Thyroid Cancer - Recent Pipeline Updates 71
Papillary Thyroid Cancer - Dormant Projects 102
Papillary Thyroid Cancer - Discontinued Products 103
Papillary Thyroid Cancer - Product Development Milestones 104
Featured News & Press Releases 104
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 105
Disclaimer 106

List of Tables

Number of Products under Development for Papillary Thyroid Cancer, H1 2016 8
Number of Products under Development for Papillary Thyroid Cancer - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Papillary Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2016 17
Papillary Thyroid Cancer - Pipeline by Genzyme Corporation, H1 2016 18
Papillary Thyroid Cancer - Pipeline by Ignyta, Inc., H1 2016 19
Papillary Thyroid Cancer - Pipeline by Novartis AG, H1 2016 20
Papillary Thyroid Cancer - Pipeline by Pfizer Inc., H1 2016 21
Papillary Thyroid Cancer - Pipeline by Plexxikon Inc., H1 2016 22
Papillary Thyroid Cancer - Pipeline by Vaccinex, Inc., H1 2016 23
Assessment by Monotherapy Products, H1 2016 24
Number of Products by Stage and Target, H1 2016 26
Number of Products by Stage and Mechanism of Action, H1 2016 29
Number of Products by Stage and Route of Administration, H1 2016 31
Number of Products by Stage and Molecule Type, H1 2016 33
Papillary Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2016 71
Papillary Thyroid Cancer - Dormant Projects, H1 2016 102
Papillary Thyroid Cancer - Discontinued Products, H1 2016 103